Baxalta Appoints Two New Directors To The Board, Further Diversifying With Strong Biopharmaceutical Leadership Experience

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announces the appointment of two new board members. Joining the company's Board of Directors effective July 27, 2015, are Karen Ferrante, M.D., and Francois Nader, M.D., expanding the Board from seven to nine members, eight of whom are independent. Both individuals bring deep biopharmaceutical expertise and a variety of distinguished professional experiences to Baxalta.

"I am pleased to welcome Karen Ferrante and Francois Nader to the Baxalta Board of Directors"

"I am pleased to welcome Karen Ferrante and Francois Nader to the Baxalta Board of Directors," said Wayne Hockmeyer, Ph.D., chairman of the Baxalta Board. "I am confident that their guidance will bring valuable insight to our Board as we continue to help Baxalta build a purpose-driven culture that delivers strong growth performance for shareholders, breakthroughs for patients, and meaningful and sustained value for all stakeholders."

Karen Ferrante, M.D., has more than 20 years of broad oncology drug development experience and demonstrated leadership across the pharmaceutical industry at both large corporations and small biotech firms. Since April 2014, Dr. Ferrante has served as chief medical officer and head of R&D at Tokai, playing a key role in the firm's successful IPO in September 2014. Prior to Tokai, Dr. Ferrante spent six years, 2007 to 2013, at Takeda Pharmaceutical Company and Millennium: The Takeda Oncology Company, serving most recently as head of Takeda's Oncology Therapeutic Area. Prior to Millennium, Dr. Ferrante spent eight years, 1999 to 2007, in Global Research and Development at Pfizer and was appointed vice president of Global Research and Development and therapeutic area clinical leader in Oncology Development in 2007. Dr. Ferrante began her pharmaceutical career in 1995 at Bristol-Myers Squibb as associate director of Clinical Oncology, focusing on drug development and team leadership. Dr. Ferrante earned her Bachelor of Science in Chemistry and Biology from Providence College in 1980 and her Doctor of Medicine from Georgetown University in 1988. From 1988 to 1991, she pursued her clinical fellowship at the New England Deaconess Hospital, a teaching hospital of Harvard Medical School.

Francois Nader, M.D., joins the Baxalta Board of Directors with more than 30 years of global biopharmaceutical industry experience in senior operational and scientific roles. From 2008 to 2015, Dr. Nader served as the president and chief executive officer of NPS Pharmaceuticals, Inc. and previously served as chief operating officer in 2007 and chief medical and commercial officer in 2006. Before NPS, Dr. Nader was a venture partner at Care Capital. Prior to that, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions in the U.S. and Canada, including senior vice president, U.S. integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon in 1981 and his Physician Executive MBA from the University of Tennessee in 2000.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients' lives, Baxalta's broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International Inc., Baxalta's heritage in biopharmaceuticals spans decades. Baxalta's therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

Contacts

Baxalta Media Relations
Lauren Denz
+1-224-948-3259
[email protected]
Baxalta Investor Relations
Mary Kay Ladone
+1-224-948-3371
[email protected]
Lorna Williams
+1-224-948-3511
[email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.